Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

PharmaCyte Biotech (PMCB) EBT (2016 - 2026)

PharmaCyte Biotech (PMCB) has disclosed EBT for 16 consecutive years, with -$630512.0 as the latest value for Q3 2025.

  • On a quarterly basis, EBT rose 12.61% to -$630512.0 in Q3 2025 year-over-year; TTM through Jul 2025 was -$2.9 million, a 172.75% decrease, with the full-year FY2025 number at -$3.0 million, down 185.4% from a year prior.
  • EBT was -$630512.0 for Q3 2025 at PharmaCyte Biotech, up from -$812788.0 in the prior quarter.
  • In the past five years, EBT ranged from a high of $6.2 million in Q2 2024 to a low of -$1.9 million in Q4 2022.
  • A 5-year average of -$561571.4 and a median of -$812788.0 in 2025 define the central range for EBT.
  • Peak YoY movement for EBT: soared 3521.74% in 2024, then crashed 113.17% in 2025.
  • PharmaCyte Biotech's EBT stood at -$980837.0 in 2021, then tumbled by 91.62% to -$1.9 million in 2022, then surged by 72.58% to -$515339.0 in 2023, then tumbled by 40.39% to -$723498.0 in 2024, then grew by 12.85% to -$630512.0 in 2025.
  • Per Business Quant, the three most recent readings for PMCB's EBT are -$630512.0 (Q3 2025), -$812788.0 (Q2 2025), and -$704560.0 (Q1 2025).